

Endoplasmic reticulum-localized hepatic lipase decreases triacylglycerol storage and VLDL secretion

Bruce Erickson^{a,b,1}, Senthamil Paramadayan Selvan^{a,b,1}, Kerry W.S. Ko^{a,b}, Karen Kelly^{a,c}, Ariel D. Quiroga^{a,b}, Lena Li^{a,b}, Randy Nelson^{a,b}, Kirst King-Jones^d, René L. Jacobs^{a,c}, Richard Lehner^{a,b,e,*}

^a Group on Molecular and Cell Biology of Lipids, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

^b Department of Pediatrics, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

^c Department of Agricultural, Food & Nutritional Sciences, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

^d Faculty of Science, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

^e Department of Cell Biology, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

ARTICLE INFO

Article history:

Received 20 October 2012

Received in revised form 9 January 2013

Accepted 23 January 2013

Available online xxx

Keywords:

Hepatic lipase

Triacylglycerol

VLDL

apoB

Fatty acid oxidation

Endoplasmic reticulum

ABSTRACT

Hepatic triacylglycerol levels are governed through synthesis, degradation and export of this lipid. Here we demonstrate that enforced expression of hepatic lipase in the endoplasmic reticulum in McArdle RH7777 hepatocytes resulted in a significant decrease in the incorporation of fatty acids into cellular triacylglycerol and cholesteryl ester accompanied by attenuation of secretion of apolipoprotein B-containing lipoproteins. Hepatic lipase-mediated depletion of intracellular lipid storage increased the expression of peroxisome proliferator-activated receptor α and its target genes and augmented oxidation of fatty acids. These data show that 1) hepatic lipase is active in the endoplasmic reticulum and 2) intracellular hepatic lipase modulates cellular lipid metabolism and lipoprotein secretion.

© 2013 Published by Elsevier B.V.

1. Introduction

Hepatic steatosis, the leading cause of abnormal liver functions, is strongly associated with obesity, insulin resistance/type 2 diabetes and cardiovascular disease [1–5]. In addition, steatosis precedes liver fibrosis, cirrhosis and hepatocellular carcinoma [1,6]. Hepatic steatosis ensues when the rate of fatty acid (FA) esterification into triacylglycerol (TG) exceeds the rate of FA output through oxidation and very-low density lipoprotein (VLDL) secretion. It is now well documented that lipolysis of hepatic TG stores by the cytosolic adipose triglyceride lipase (ATGL) provides FA for oxidation [7–10] and that attenuation of ATGL

activity leads to hepatic TG accumulation [8,9,11]. On the other hand, an endoplasmic reticulum (ER)-associated carboxylesterase3/triacylglycerol hydrolase mobilizes stored TG for VLDL secretion [12–16].

Hepatic lipase (HL) is a lipase secreted from the liver. HL exhibits phospholipase A₁ and TG hydrolase activities and is involved in the metabolism of plasma lipids present in high-density lipoproteins (HDL) and in VLDL [17–20]. Aside from its lipolytic function, HL also facilitates the selective uptake of cholesteryl esters (CE) from HDL [21–24] as well as the removal of apoB-containing lipoprotein remnants via receptor mediated endocytosis [20,25–27]. These mechanisms ultimately clear excess lipid from the circulation. Yet, whether HL expedites or delays the onset of atherosclerosis remains controversial [28]. Lipids that HL accesses have been so far limited to the extracellular compartment (plasma and cell surface). However, because HL is a secreted protein it is also present in the ER and along the secretory route for a limited period of time prior to secretion. We hypothesized that HL attains its lipolytic activity intracellularly and it may therefore be capable of modulating intracellular TG pools. Several secreted and plasma membrane proteins have been already shown to play an intracellular role in TG export via VLDL, in addition to their roles in lipoprotein metabolism within the plasma compartment or at the cell surface. These include apoE [29–31], phospholipid transfer protein [32,33] and low-density lipoprotein (LDL) receptor [34]. HL is likely to gain its lipolytic activity along the

Abbreviations: apoB, apolipoprotein B; ATGL, adipose triglyceride lipase; CE, cholesteryl ester; DG, diacylglycerol; ER, endoplasmic reticulum; E600, diethyl-*p*-nitrophenylphosphate; FA, fatty acid; HL, hepatic lipase; HL-R, ER-retained hepatic lipase; McA, McArdle-RH7777; PBS, phosphate-buffered saline; MTP, microsomal triglyceride transfer protein; OA, oleic acid; PC, phosphatidylcholine; PDI, protein disulfide isomerase; PL, phospholipids; Ppia, cyclophilin; R12, McArdle cells expressing HL-R; TG, triacylglycerol; VLDL, very-low density lipoprotein

* Corresponding author at: Group on Molecular and Cell Biology of Lipids, 328 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, Canada T6G 2S2. Tel.: +1 780 492 2963; fax: +1 780 492 3383.

E-mail address: richard.lehner@ualberta.ca (R. Lehner).

¹ B. Erickson and S.P. Selvan contributed equally to this work.

secretory pathway [25,35]. Recent studies strongly suggest that over-expression of secretion-competent HL resulted in diminished lipid levels within the endoplasmic reticulum and in the reduction of TG in the media [36], however the precise mechanism by which the secreted HL affected cellular lipid metabolism (extracellular vs intracellular role) remains unclear. To establish whether HL promotes the mobilization of lipids intracellularly, we generated McArdle-RH7777 (McA) cells stably expressing a cDNA encoding mouse HL chimera that enforces HL retention in the ER and investigated whether the expression of this intracellularly retained HL affects lipid metabolism.

2. Theory

Secreted HL has been shown to diminish intracellular lipid levels and VLDL secretion. We hypothesize that HL becomes active in the secretory pathway and this intracellular activity diminishes substrate availability for the assembly of VLDL.

3. Materials and methods

3.1. Generation of McA cells stably expressing mouse HL cDNA

Mouse cDNAs encoding FLAG-tagged secretion-competent mouse HL (HL-S) or intracellularly retained HL (HL-R) were generated. The forward primer contained a sequence of the coding region of the cDNA and an XhoI restriction site (underlined) [5'-C CTA CTC GAG GGT AAG ACG AGA GAC ATG GGA AAT CCC CT-3']. The reverse primer, corresponding to the complementary strand, encoded an XbaI restriction site (underlined) [5'-A CGT TCT AGA GAA TAG ACT TCT TTA TTT TTT TGC ATG GG-3']. These primers were used to amplify the HL cDNA (~1.6 kb) from a mouse liver Igt11 cDNA library [37]. Amplification was performed at 93 °C 1 min, 60 °C 1 min, 72 °C 2 min for 30 cycles. The PCR product was digested and ligated into XhoI and XbaI sites of pBluescript II SK-plasmid (Stratagene) and the entire cDNA was sequenced. The plasmid was used as a template to generate chimeric cDNA encoding the mouse HL protein with the FLAG epitope at the extreme C-terminus (HL-secreted; HL-S) or with the FLAG epitope followed by the mammalian ER retrieval signal—HVEL (HL-retained; HL-R) at the extreme C-terminus [14,38]. The reverse primer for HL-S [5'-CT AGT CTA GAC TAG TCA CTT ATC GTC GTC ATC CTT GTA ATC TTT TTT TGC ATG GGT CTC TTG ACT CAT CTG C-3'] and for HL-R [5'-T CAT TCT AGA TCA CAG TTC AAC ATG CTT ATC GTC GTC ATC CTT GTA ATC TTT TTT TGC ATG GGT CTC TTG ACT CAT CTG C-3'] corresponding to the complementary strand contained the FLAG sequence (underlined), and the HL-R primer also encoded the ER retrieval signal (bold). The aforementioned forward primer was common for both chimeric HL cDNAs. The resultant PCR product was cloned into the pCR4-TOPO plasmid (Invitrogen) and sequenced. The chimeric cDNA was excised from this plasmid using XhoI and SpeI and was ligated into a XhoI and XbaI digested pCI-neo (Promega) mammalian expression vector. Wild-type McA were stably transfected [12] with pCI-neo vector (no insert, control), with pCI-neo vector encoding FLAG-tagged secretion-competent mouse HL (HL-S), or with pCI-neo vector encoding FLAG-tagged intracellularly retained HL (HL-R). Individual HL expressing clones were isolated and analyzed for HL levels by immunoblotting with anti-FLAG antibodies. Intracellular localization of mouse HL chimeras was determined by density gradient subcellular fractionation [14,39,40] and by colocalization with ER marker protein disulfide isomerase (PDI) using confocal laser scanning immunofluorescence microscopy [14,40,41]. Lipolytic activities in cell lysates, media and microsomes prepared from stable cell lines and primary mouse hepatocytes were analyzed using the TG analogue 1,2-dilauryl-rac-glycero-3-glutaric acid resorufin ester [42].

3.2. Generation of adenovirus encoding HL-R and infection of McA cells

Adenovirus encoding both the green fluorescent protein (GFP) and HL-R was generated (SignaGen Laboratories, Rockville, MD, USA). Adenovirus encoding only GFP was used as control in infection experiments. McA cells were infected with 100×10^6 pfu of either adeno-HLer or adeno-GFP for 24 h. Cells were then washed with DMEM and used for experiments.

3.3. Lipid synthesis and turnover

Cells were washed and incubated in serum-free DMEM for 4 h either in the absence or presence of 0.4 mM oleic acid (OA) complexed to 0.5% BSA [12]. For analyses of lipid turnover, media after the initial 4 h incubations were aspirated, cells were washed three times with serum-free DMEM containing 0.5% FA free BSA, and were incubated for an additional 16 h in serum-free DMEM. Cells and media were then collected for analyses. Lipids from cell lysates and cell-free media were extracted and quantified by gas chromatography as previously described [43].

For studies investigating lipid synthesis and turnover, cells were treated exactly as described above for lipid synthesis, turnover and secretion studies except that the initial 4 h incubations also contained either 2.5 μ Ci/mL [9,10(n)- 3 H]OA or 1 μ Ci/mL [14 C]glycerol. Lipids were spotted on thin-layer chromatography (TLC) plates and resolved with a two-solvent system as described previously [13]. TG, CE, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) bands were isolated and radioactivity was determined by scintillation counting. In some experiments radioactive lipids were detected by fluorography by spraying the TLC plates with Amersham Amplify™ Fluorographic Reagent (GE Healthcare) and exposure to BioMax MR films (Kodak).

To address the participation of ER-retained HL in the turnover of preformed lipid stores, cells were first incubated with radiolabeled OA as described above but in the presence of a pan-lipase inhibitor 100 μ M diethyl-*p*-nitrophenylphosphate (E600) in order to inhibit all intracellular TG turnover. The inhibitor was then removed, cells were then washed and further incubated for up to 16 h in DMEM. Lipids from cell lysates and cell-free media were extracted at various times as indicated and processed as described above.

Acid-soluble metabolites (ASM), a measurement of fatty acid oxidation was determined in media. First, 20% BSA was added to media followed by 70% perchloric acid and centrifugation at $21,000 \times g$ for 5 min. Aliquot of the supernatant was counted for radioactivity [39].

3.4. ApoB secretion

ApoB from culture media was immunoprecipitated with goat anti-apoB antibodies (Chemicon) followed by capture of immunocomplexes on protein A-Sepharose beads (Sigma). Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with anti-apoB antibodies. ApoB concentrations were quantified by densitometry analysis using QuantityOne software (BioRad).

3.5. Gene expression analysis

Total RNA was isolated from cells using Trizol® reagent (Life Technologies, Inc.) and reverse transcribed using Superscript II (Invitrogen). Primer sets, and a corresponding probe for each gene of interest were designed using the Universal Probe Library (Roche) based on the NCBI reference nucleotide sequences for *Rattus norvegicus*. Each primer pair and probe combination were previously tested by qPCR. Forty-eight gene assays were loaded into separate wells on a 48-by-48 gene expression chip (Fluidigm). qPCR was run on the Biomark™ system (Fluidigm) for 40 cycles. Relative RNA expression for each gene in a sample was standardized to cyclophilin, and calculated using the comparative

191 threshold ($\Delta\Delta C_t$) method. Values were normalized to an endogenous
192 housekeeping gene cyclophilin (Ppia).

193 3.6. Statistical analysis

194 The results are expressed as means \pm SEM. Statistical analysis was
195 performed by a student *T*-test or one-way ANOVA with a Newman–
196 Keuls post test using GraphPad Prism software. *P* values <0.05 were
197 considered statistically significant.

198 4. Results

199 4.1. Intracellular HL is active

200 To determine the potential role of HL on intracellular lipid metabo-
201 lism, we produced two cDNA constructs. The first construct, HL-
202 secreted (HL-S), encodes the full-length murine HL cDNA with a se-
203 quence encoding the FLAG epitope (DYKDDDDK) immediately before
204 the stop codon. The second construct, HL-retained (HL-R), encodes the
205 full-length murine HL cDNA with an additional sequence following the
206 FLAG epitope encoding the mammalian ER retrieval signal (HVEL),
207 which is present in ER-localized mouse carboxylesterase 3/triacylglycerol
208 hydrolase and carboxylesterase 1/Es-x [39,44], immediately before the
209 stop codon (Fig. 1A and Supplemental Fig. S1A). These constructs were
210 inserted into pCI-neo plasmid used for transfection of McA cells. Several
211 McA clones stably expressing variable levels of HL-S and HL-R were iso-
212 lated and tested for HL expression, activity and cellular lipid metabolism.
213 Experiments were conducted with a clone R12 stably McA expressing
214 HL-R (Fig. 1B) and a clone S7 stably expressing HL-S (Supplemental Fig.
215 S1A). Some experiments were also performed with additional HL-S
216 clone S1 and HL-R clone R5 (Supplemental Fig. S2).

217 HL-R is retained within McA cells (Fig. 1B) and is barely detectable in
218 media following a 16 h incubation as measured by immunoblotting and
219 lipase activity (Supplemental Fig. S1A, B). Furthermore, HL-R is distrib-
220 uted in a reticular pattern within the cell similar to the ER resident pro-
221 tein PDI (Fig. 1C). Importantly, intracellularly retained HL is catalytically
222 active as demonstrated by a 3-fold increase of lipolytic activity in micro-
223 somes isolated from R12 cells compared to microsomes prepared from
224 control pNEO1 (control) cells (Fig. 1D). Relatively low levels of HL-S
225 could be detected in cell lysate from S7 cells, while high levels of HL-S
226 were found in the media (Supplemental Fig. S1A). Media from S7 cells
227 exhibited increased lipolytic activity compared to media from either
228 R12 or pNEO1 cells (Supplemental Fig. S1B) and this activity was only
229 about 20% higher than that present in media from cultures of primary
230 mouse (C57BL/6) hepatocytes after the same incubation period (Sup-
231 plemental Fig. S1C). Therefore, S7 cells appear to secrete a comparable
232 amount of HL as primary mouse hepatocytes. Furthermore, S7 cell ly-
233 sates showed a 50% increase in lipolytic activity compared to pNEO1 mi-
234 crosomes (Supplemental Fig. S1B), suggesting that intracellularly
235 localized HL destined for secretion is catalytically active along the exo-
236 cytotic pathway.

4.2. Intracellular HL activity prevents lipid accumulation

237
238 Because the intracellular HL-R is active, we postulated that the lipase
239 might hydrolyze its native substrates (TG and glycerophospholipids)
240 within the ER and therefore affect lipid storage and VLDL secretion.
241 We performed experiments to study lipid turnover and apoB secretion
242 in McA cells stably transfected with pNEO1 (control) and HL-R and HL-S
243 vectors, as well as, with McA cells infected with adenovirus encoding
244 HL-R. Cells were incubated with 0.4 mM OA for 4 h to stimulate lipid
245 synthesis [12]. Cellular TG mass increased from 6.5 μ g/mg cell protein
246 in untreated cells (no OA supplementation) to 22 μ g/mg of cell protein




Fig. 1. Generation of McA stably transfected cell lines. (A) Schematic depiction of FLAG-tagged ER-retained HL (HL-R) chimera. (B) Immunoblot of expressed HL-R in McA cell lysates. pNEO1 are cells stably transfected with empty vector, R12 are cells stably transfected with HL-R. PDI (protein disulfide isomerase) is an ER-localized protein containing a similar ER-retention signal (KDEL) and was used as the loading control. (C) Localization of FLAG-tagged HL-R in transfected McA cells by confocal immunofluorescence microscopy. (D) Lipase activity in microsomal fractions isolated from control (pNEO1) and HL-R expressing (R12) McA cells. **P*<0.001 versus control pNEO1.

247 in oleate supplemented pNEO1 cells and from 2 $\mu\text{g}/\text{mg}$ cell protein to
 248 13 $\mu\text{g}/\text{mg}$ cell protein in HL-R cells (Fig. 2A). OA supplementation did
 249 not affect PC or PE mass or the levels of unesterified cholesterol (FC) (re-
 250 sults not shown). Although OA significantly augmented intracellular TG
 251 concentrations in both cell lines, TG mass remained significantly lower
 252 in the HL-R expressing R12 cells compared to the control pNEO1 cells
 253 (Fig. 2A). Comparably decreased accumulation of TG upon OA incuba-
 254 tion was also observed in another HL-R clone R5 (Supplemental Fig.
 255 S2B, C). R12 cells were also significantly depleted of cellular CE relative
 256 to pNEO1 cells (Fig. 2A). This suggests that intracellular HL hydrolyzed
 257 neutral lipids formed from exogenously supplied OA. Further incuba-
 258 tion of cells in the absence of OA (16 h) resulted in depletion of 56%
 259 of TG and 35% of CE in the control pNEO1 cells and 53% of TG and 32%
 260 of CE in R12 cells (Fig. 2A). Because the rate of depletion of preformed
 261 TG and CE in R12 cells was comparable to the control pNEO1 cells,
 262 this result suggests that the ER-localized HL did not participate in the
 263 hydrolysis of preformed stored neutral lipids. Decreased accumulation
 264 of TG in HL-R expressing cells was accompanied by diminished levels
 265 of the lipid droplet associated protein perilipin 2 (Fig. 2B).

266 To address the mechanism of neutral lipid lowering by intracellular HL
 267 expression, radiolabeled OA pulse/chase experiments were undertaken.

268 Incorporation of exogenously supplied OA into glycerolipids and
 269 cholesteryl ester was significantly decreased in HL-R expressing
 270 cells, while the level of intracellular free radiolabeled fatty acid was
 271 not different between control and HL-R expressing cells (Fig. 3A,
 272 B). Interestingly, while the radioactivity in most glycerolipids in
 273 HL-R expressing cells was decreased, the cells appeared to accumu-
 274 late radiolabeled monoacylglycerol (MG) during the pulse period
 275 suggesting active lipolysis of TG and DG, however the radioactivity
 276 in MG was too low for performing statistical analysis with confidence
 277 (Fig. 3A). The rate of disappearance of radioactivity from preformed
 278 OA-labeled TG pools (chase period) was similar between control and
 279 HL-R expressing cells, 70% in control cells and 75% in HL-R express-
 280 ing cells, indicating that other lipases are responsible for the turn-
 281 over of stored cytosolic TG pools. Although lower incorporation of
 282 OA into glycerophospholipids (PC and PE) was observed in HL-R ex-
 283 pressing cells, the turnover of the radioactivity in these lipids was
 284 similar between control and HL-R expressing cells (Fig. 3B). Howev-
 285 er, differences were observed in the turnover of CE. Control cells
 286 turned over about 50% of radiolabel in CE, while HL-R expressing
 287 cells showed accelerated CE turnover resulting in depletion of 90%
 288 of radiolabel during the same incubation period (Fig. 3B).




Fig. 2. HL-R depletes neutral lipid stores. (A) Analysis of cellular TG and CE mass in control and HL-R expressing McA cells grown to ~70% confluency (untreated, -OA), after incubation with OA (+OA) and after additional incubation in the absence of OA following initial OA supplementation (+OA/-OA). Data are shown as the mean \pm SEM for $n = 3-4$ experiments performed in triplicate. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus control pNEO1. (B) Immunoblot analysis of a lipid droplet associated protein perilipin 2 in control and HL-R expressing cells.




Fig. 3. HL-R decreases lipid accretion. (A) Incorporation of [³H]OA into lipids determined by TLC and fluorography. SM, sphingomyelin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; MG, monoacylglycerol; DG, diacylglycerol; FA, free fatty acid (i.e. OA); TG, triacylglycerol; CE, cholesteryl ester. (B) Radioactivity in lipids in cells after radiolabeled pulse with [³H]OA and chase (absence of OA). Values are the mean \pm SEM for $n = 3$ –4 experiments performed in triplicate. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus control pNEO1.

289 In addition to cell lines stably expressing HL-R we have also
 290 performed studies in McA cells infected with HL-R encoding adenovirus.
 291 Cells infected for 24 h expressed active HL-R (Ad-HLer) intracellularly
 292 (Fig. 4A, B), though the levels of protein expression were lower
 293 compared to the R12 clone stably expressing HL-R. No immunodetectable
 294 HL-R was observed in the media of infected cells (data not shown).
 295 Similarly to cells stably expressing HL-R (R12, R5), ad-HLer significantly
 296 decreased the amounts of radiolabeled cellular glycerolipid and CE upon
 297 incubation of cells with 0.4 mM [³H]OA for 4 h (Fig. 5).

299 Compared to the ER-retained HL (HL-R) as expected the secretion
 300 competent HL (HL-S) had a more moderate effect on the incorporation
 301 of radiolabeled OA into cellular lipids due to its transitory localization
 302 in the intracellular lipid synthetic compartment. Nevertheless,
 303 incorporation of OA into TG was decreased by 30% (Supplemental
 304 Table S1A), while incorporation of OA into PC was not statistically different.
 305 Decrease in incorporation of OA into TG in HL-S expressing cells was
 306 also observed in the presence of 50 μ M poloxamer 407
 307 (Supplemental Table S1B). This is the detergent concentration that
 308 inhibited 100% of HL activity in the media without affecting




Fig. 4. Infection of MCA cells with adenovirus encoding ER-retained HL (HLer). (A) Immunoblot of expressed HLer in MCA cell lysates. Calnexin (an ER-localized protein) was used as the loading control. (B) Lipase activity is cell lysates against resorufin ester. * $P < 0.05$ versus control pNEO1.

4.3. Mobilization of preformed lipids

Lipid mass turnover and pulse/chase experiments (Figs. 2 and 3) suggested that intracellular HL does not participate in the mobilization (hydrolysis) of preformed lipids. However, due to significantly diminished generation of lipid stores in HL-R cells the rate of turnover of preformed lipids could have been influenced by decreased substrate availability. Therefore, in order to be able to make a more precise comparison of turnover of preformed lipids in the two cell lines, the cells should have equal amounts of available substrate with similar specific radioactivity. We therefore first incubated cells with OA in the presence of lipase inhibitor diethyl-*p*-nitrophenylphosphate (E600) that blocks all lipolysis [13] and thus initial neutral lipid (TG and CE) accretion in both control and HL-R expressing cells was equal upon incubation with 0.4 mM [3 H]OA (Fig. 6A). Similarly, OA incorporation into PE was not different between control and HL-R expressing cells in the presence of the lipase inhibitor, while the incorporation of OA into PC was significantly increased (46%). These results demonstrate that the decreased incorporation of exogenously supplied OA into lipids observed in the absence of lipase inhibitor (Figs. 2 and 3) was due to the lipolytic activity of HL-R. Incorporation of glycerol into both TG and PC was augmented in HL-R expressing cells (Fig. 6B). The rate of turnover of preformed TG during subsequent 16 h incubation after removal of E600 was similar between control and HL-R expressing cells indicating that HL-R did not access preformed lipid storage pools (Fig. 6A, B). Interestingly, CE levels increased during the 16 h "Chase" incubation when the only possible substrate would need to come from preformed labeled lipids.




Fig. 5. Adenovirus-mediated HLER expression decreases lipid accretion. Radioactivity in cellular lipids after 4 h radiolabeled pulse with 0.4 mM [3 H]OA. Values are the mean \pm SEM for $n = 3$ experiments. * $P < 0.05$ versus control pNEO1.




Fig. 6. HL-R does not access preformed stored lipid pools. (A) Incorporation of [³H]OA into lipids in the presence of the lipase inhibitor (+E600) and turnover of preformed lipids after removal of the inhibitor (−E600). (B) Incorporation of [¹⁴C]glycerol into lipids in the presence of 0.4 mM OA and the lipase inhibitor (+E600) and turnover of preformed lipids after removal of the inhibitor (−E600). Values are the mean ± SEM for n = 3–4 experiments performed in triplicate. *P < 0.05, **P < 0.01 versus control pNEO1.

340 4.4. Intracellular HL activity attenuates VLDL secretion

341 TG and CE are the major neutral lipid components of VLDL. Be-
 342 cause HL-R expression reduced intracellular TG and CE levels, we hy-
 343 pothesized that this could lead to diminished lipid availability for
 344 VLDL assembly and reduced apoB secretion.

345 Even in the presence of exogenous OA-mediated TG synthesis
 346 (Pulse period), the secretion of apoB100 from R12 cells was decreased
 347 by 85% (Fig. 7A). Secretion of apoB48 from all McA cell lines was very
 348 low (Fig. 7A). No significant change in apoB secretion from HL-S ex-
 349 pressing S7 cells was observed in the presence of OA (Supplemental
 350 Table S1C). Upon removal of OA from the culture media and cessation
 351 of TG synthesis by exogenously supplied FA (chase period), apoB

secretion from HL-R expressing R12 cells was almost completely
 352 abolished (Fig. 7A), while HL-S expressing S7 cells secreted 30% less
 353 apoB100 than control cells (Supplemental Table S1C). ApoE secretion
 354 was unchanged by the expression of HL-R (Fig. 7A). These results em-
 355 phasize the fact that apoB100 secretion from McA cells is dependent
 356 on sufficient availability of TG [45–47]. Expression of HL-R resulted
 357 in an 80–90% decrease of TG secretion into the media during both
 358 the pulse and the chase (Fig. 7B). HL-S expressing S7 cells also secreted
 359 diminished amounts (40%) of TG in OA-supplemented (Pulse) and
 360 after OA withdrawal (Chase) (Supplemental Table S1C). Significant
 361 decrease of TG and CE secretion was also observed in McA cells
 362 infected with ad-HLer following 4 h incubation with 0.4 mM [³H]OA
 363 (Supplemental Fig. 4A). Therefore, HL has the ability to markedly
 364




Fig. 7. HL-R attenuates VLDL secretion. (A) Immunoblot of media apoproteins and quantitation of apoB. * $P < 0.001$ versus control pNEO1. (B) Mass and radioactivity of media TG after incubation with 0.4 mM $[^3\text{H}]\text{OA}$ (Pulse + OA) followed by incubation in the absence of OA (Chase-OA). Values are mean \pm SEM for $n = 3-4$ experiments performed in triplicate. ** $P < 0.01$ versus control pNEO1. (C) Immunoblot of MTP and a loading control protein disulfide isomerase (PDI) in McA cell lysates. (D) Ketone body accumulation in McA cell media after incubation for 4 h with 0.4 mM OA. Values are mean \pm SEM ($n = 3$). ** $P < 0.01$ versus control pNEO1.

365 reduce TG secretion via its activity within the ER compartment. Mi-
 366 crosomal triglyceride transfer protein (MTP) plays a crucial role in
 367 the initial step of apoB folding and assembly [48]. Although the *Mtp*
 368 mRNA levels in R12 cells were increased 8-fold (Table 1) the MTP
 369 protein levels were significantly diminished (Fig. 7C). These results
 370 suggest rapid degradation of the MTP in R12 cells.

371 4.5. Intracellular HL activity causes changes in the expression of lipogenic 372 and oxidative genes

373 HL-R expressing R12 cells (OA-supplemented) exhibited significant
 374 changes in the expression of lipid uptake, lipogenic and oxidative
 375 genes compared to control cells (Table 1). The expression of key tran-
 376 scription factors regulating lipogenesis (LXR β), cholesterologenesis

(SREBP2) and FA oxidation (PPAR α) was increased as was the expres- 377
 sion of the respective target genes, such as LXR β /SREBP1c targets 378
 diacylglycerol acyltransferase 1, mitochondrial glycerol-3-phosphate 379
 acyltransferase, and acetyl-CoA carboxylase; SREBP2 target LDL recep- 380
 tor, PPAR α targets carnitine palmitoyltransferase-1 and acyl-CoA dehy- 381
 drogenases (Table 1). The augmented expression of FA oxidation genes 382
 was accompanied by increased production of ketone bodies in R12 cells 383
 (Fig. 7D) and the production of acid-soluble metabolites (ASM) in 384
 ad-HLer infected cells (Supplemental Fig. S4B). This increased fatty 385
 acid oxidation may be responsible for the lack of cellular accumulation 386
 of FA released by HL-mediated lipolysis and for decreased accumulation 387
 of lipids despite significant attenuation of VLDL secretion. The most 388
 striking change in expression was observed for Pck1 gene encoding 389
 phosphoenolpyruvate carboxykinase 1 (PEPCK), which was increased 390

Table 1

HL-R upregulates expression of lipogenic and oxidative genes.

| Function | Gene | pNEO1 | R12 | P-value |
|---------------------------------------|---------------|-------------|--------------|-------------|
| Lipid synthesis | Mogat1 | 1.08 ± 0.12 | 1.63 ± 0.06 | 0.0066 |
| | Dgat1 | 1.01 ± 0.09 | 1.29 ± 0.05 | 0.0351 |
| | Gpam | 1.07 ± 0.28 | 4.28 ± 0.65 | 0.0105 |
| Lipid uptake | Lipin2 | 1.05 ± 0.24 | 1.72 ± 0.11 | 0.0385 |
| | Chka | 1.03 ± 0.17 | 4.04 ± 0.10 | <0.0001 |
| | Acaca | 1.16 ± 0.46 | 2.68 ± 0.11 | 0.0136 |
| | Scarb1 | 1.01 ± 0.07 | 1.79 ± 0.11 | 0.0028 |
| | Slc27a1 | 1.09 ± 0.34 | 8.08 ± 0.52 | 0.0001 |
| Lipid oxidation | Ldlr | 1.19 ± 0.52 | 3.57 ± 0.26 | 0.0066 |
| | Cpt1a | 1.18 ± 0.48 | 3.30 ± 0.28 | 0.0098 |
| | Acadl | 1.10 ± 0.36 | 2.80 ± 0.20 | 0.0066 |
| Lipid secretion | Acadvl | 1.00 ± 0.04 | 2.18 ± 0.18 | 0.0026 |
| | Mttp | 1.11 ± 0.37 | 8.10 ± 0.51 | 0.0001 |
| Gluconeogenesis/ glyceroneogenesis | Pck1 | 1.29 ± 0.56 | 101.4 ± 2.82 | <0.0001 |
| | Transcription | Nr1h2/LXRb | 1.01 ± 0.08 | 1.41 ± 0.05 |
| ER stress | Sreb1f2 | 1.07 ± 0.28 | 2.09 ± 0.24 | 0.0416 |
| | Ppara | 1.15 ± 0.44 | 4.24 ± 0.27 | 0.0014 |
| | Hspa5/BiP | 1.00 ± 0.07 | 0.22 ± 0.01 | <0.0001 |

Values are expressed as mean ± SEM.

Abbreviations: Mogat1, monoacylglycerol O-acyltransferase 1; Dgat1, diacylglycerol O-acyltransferase 1; Gpam, glycerol-3-phosphate acyltransferase (mitochondrial); Lipin2, Lipin 2; Chka, choline kinase a; Acaca, acetyl-coenzyme A carboxylase a; Scarb1, scavenger receptor class B-member 1; Slc27a1, solute carrier family 27 (fatty acid transporter) member1/FATP-1; Ldlr, low density lipoprotein receptor; Cpt1a, liver carnitine palmitoyltransferase1; Acadl, acyl-coenzyme A dehydrogenase-long chain; Acadvl, acyl-coenzyme A dehydrogenase-very long chain; Ppara, peroxisome proliferator-activated receptor α ; Mttp, microsomal triglyceride transfer protein; Pck1, phosphoenolpyruvate carboxykinase 1 (soluble); Nr1h2, nuclear receptor subfamily 1-group-h-member3/LXR β ; Sreb1f2, sterol regulatory element binding transcription factor 2; Hspa5, heat shock protein 70 kDa protein 5/BiP.

100-fold (Table 1). It is worth noting that no significant changes in the expression were observed for several key lipogenic genes including *Lxra*, *Sreb1c*, *Fas*, *Scd1*, *Dgat2*, *Mgat2*, *Agpat2*, *lipin1* and fatty acid oxidation genes *Mcad* and *Acox1*.

5. Discussion

This study was conducted to test the hypothesis that HL becomes active within the ER and is capable of modulating VLDL assembly and secretion. Surprisingly, expression of ER-targeted HL in McA cells not only decreased VLDL secretion but also lowered cellular TG accumulation. Our data are consistent with HL-catalyzed hydrolysis of *de novo* formed DG, TG and glycerophospholipids within the ER. The prolonged residence of HL-R in the ER also likely diminishes the TG pool available for bulk lipidation of lipid-poor primordial apoB particles due to diminished levels of MTP [49–51]. An attractive hypothesis is that reduced MTP- and lipid-mediated co-translational/co-translocational lipidation of apoB results in augmented apoB degradation by the proteasome or by autophagy. FA released by HL-catalyzed lipolysis do not accumulate but are oxidized and possibly also effluxed into the culture media. Importantly, our data indicate that FA generated by lipolysis within the ER bilayer can serve as ligands for PPAR α activation and as substrates for mitochondrial β -oxidation. Previously, only arylacetamide deacetylase, a diacylglycerol (DG) lipase, [52] and ATGL, a lipase associated with hepatic cytosolic lipid droplets, have been shown to support this process [7,10,53]. The lipid lowering effect of HL-R appeared to be dependent on the lipolytic activity of HL since no reduction in cellular TG was observed upon incubation of HL-R expressing cells with a pan-lipase inhibitor E600. Our results are in agreement with a recent report by Bamji et al. who showed that secretion-competent human HL (analogous to HL-S in this study) was able to decrease intracellular TG levels and TG secretion in the same cell hepatoma line. Interestingly, expression of secretion-competent inactive HL (catalytic serine residue

mutated to glycine) has been recently reported to diminish TG secretion without affecting intracellular lipid levels [36]. The mechanism by which inactive HL affected media TG levels is currently unclear because in addition of the lack of effect on total intracellular TG levels, the partitioning of TG into the secretory pathway (ER lumen) was also not significantly altered in cells expressing the inactive HL [36]. As in this recent report by Bamji et al. [36], we also did not observe significant differences in apoB secretion in cells expressing secretion-competent HL (HL-S) during the OA supplementation period. However, we observed diminished apoB100 secretion (30%) during the subsequent chase period in the absence of exogenously supplied OA. The observed decreased OA incorporation into glycerophospholipids in HL-R expressing cells could be partially due to the phospholipase activity of HL. However, since DG levels are diminished in HL-R expressing cells and DG is the obligate precursor for both PC and PE synthesis in these cells, the decreased glycerophospholipid synthesis is more likely due to the insufficiency of DG. Because the turnover rate of the preformed lipids appeared to be independent of HL-R expression this suggests that HL-R did not access preformed stored cytosolic neutral lipids. The increased depletion of CE in HL-R expressing cells was unexpected as a CE hydrolase activity has not been previously attributed to this enzyme. It is more likely that FA for cholesterol esterification are derived from the turnover of preformed TG storage pools ([13,39] and Fig. 6), and since these pools are diminished in HL-R expressing cells this may directly impact on CE levels. Expression of HL-R resulted in augmented expression of lipogenic and fatty acid oxidation genes. This is in agreement with Bamji et al. [36] who reported upregulation of expression of *Mttp*, *Dgat2* and *Cpt1a* in cells transfected with secretion-competent HL. However, while *Mttp* mRNA was increased 8-fold in R12 cells the MTP protein was significantly reduced suggesting rapid degradation of the protein in these cells that have greatly diminished apoB lipidation/secretion capacity. On the other hand, increased *Cpt1a* and *Ppara* mRNA expression in HL-R was accompanied with the expected increased fatty acid oxidation levels. One of the most surprising findings in our study is the 100-fold increase in the expression of *Pck1* mRNA encoding PEPCK. PEPCK is a key glyceroneogenic/gluconeogenic gene and our results suggest that one of the roles of PEPCK in R12 cells might be to provide glycerol-3-phosphate backbone for PC synthesis as indicated by increased incorporation of radiolabeled glycerol into this lipid. One possible explanation is that HL-R hydrolyzes DG within the ER, which is the obligate precursor of PC synthesis and the cells compensate by upregulating the activities of enzymes in glycerophospholipid biosynthesis in order to keep allostatic balance. The net effect is compensatory increased glycerolipid synthesis with concomitant HL-catalyzed increased degradation (futile cycle) resulting in the release of FA from newly synthesized lipids, which are subsequently targeted for oxidation.

Although the effect of HL on VLDL production in humans has not been directly studied the role of HL in this process can be inferred from several findings. HL deficiency in humans is most commonly attributed to polymorphisms in the *LIPC* (gene encoding HL) promoter [54–56], which diminish transcriptional efficacy. Less common are mutations in the coding region of the gene [57–59], which alter the structural integrity, secretion and catalytic properties of HL. Patients with HL deficiency display elevated total plasma cholesterol and TG concentrations and have a lipoprotein profile characterized by markedly increased TG- and PL-rich lipoprotein remnants and HDL [60]. It is possible that lack of HL activity would augment VLDL production. Two studies in patients with compound heterozygous mutations in the coding region of *LIPC* gene provide support for this hypothesis [58,59]. Both of these studies measured plasma lipid profiles and utilized a primed-constant infusion of deuterated leucine over a 12 h period to investigate lipoprotein turnover. In both studies the VLDL apoB100 pool size in HL deficient men were approximately three-fold of those from normotriglyceridemic men and the total plasma TG levels were also highly elevated. Decreased fractional

catabolic rate certainly contributed to accumulation of VLDL apoB100 in HL deficient men from both studies but one study [58] also reported a three-fold higher hepatic VLDL apoB100 production rate.

In conclusion, our results in McA cells (a model cell line of hepatocytes) provide support for an anti-atherogenic role for HL. Treatments resulting in increased intracellular HL activity (gene therapy) may result in decreased intracellular TG levels and therefore in alleviation of pathologies associated not only with fatty liver conditions (i.e. non-alcoholic fatty liver disease), but also with hyperlipidemia (atherosclerosis) and hepatitis C virus infection since the infectivity of this virus appears to be dependent on the presence of intracellular TG stores and functional VLDL assembly and secretion pathway.

Acknowledgements

This work was supported by a grant-in-aid from the Heart and Stroke Foundation of Alberta, Northwest Territories and Nunavut awarded to R.L. and by operating grants from the Canadian Institutes of Health Research to R.L. and R.L.J. S.S.P. was supported by the University of Alberta Faculty of Medicine and Dentistry graduate studentship. A.D.Q. was supported by the Heart and Stroke of Canada postdoctoral fellowship. K.K. was supported by an Alexander Graham Bell Canada graduate scholarship from the Natural Sciences and Engineering Research Council of Canada and by a Walter H. Johns fellowship from the University of Alberta. R.L.J. is a Heart and Stroke Foundation of Canada Investigator and holds a Canadian Institutes of Health Research New Investigator award. R.L. is a Scientist of the Alberta Innovates-Health Solutions. The authors thank Audric Moses for expert technical assistance in lipid analysis. Lipid analysis by gas chromatography was performed by a Lipid Analysis Core, which receives support from the Women and Children Health Research Institute.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbali.2013.01.017>.

References

- [1] D.G. Tiniakos, M.B. Vos, E.M. Brunt, Nonalcoholic fatty liver disease: pathology and pathogenesis, *Annu. Rev. Pathol.* 5 145–171.
- [2] E. Fabbrini, S. Sullivan, S. Klein, Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications, *Hepatology* 51 679–689.
- [3] J.D. Browning, J.D. Horton, Molecular mediators of hepatic steatosis and liver injury, *J. Clin. Invest.* 114 (2004) 147–152.
- [4] K.V. Kowdley, S. Caldwell, Nonalcoholic steatohepatitis: a twenty-first century epidemic? *J. Clin. Gastroenterol.* 40 (2006) S2–S4.
- [5] B.A. Neuschwander-Tetri, S.H. Caldwell, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, *Hepatology* 37 (2003) 1202–1219.
- [6] B.Q. Starley, C.J. Calcagno, S.A. Harrison, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, *Hepatology* 51 1820–1832.
- [7] J.M. Sapiro, M.T. Mashek, A.S. Greenberg, D.G. Mashek, Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor alpha activity, *J. Lipid Res.* 50 (2009) 1621–1629.
- [8] S.M. Turpin, A.J. Hoy, R.D. Brown, C.G. Rudaz, J. Honeyman, M. Matzaris, M.J. Watt, Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice, *Diabetologia* 54 (2011) 146–156.
- [9] J.W. Wu, S.P. Wang, F. Alvarez, S. Casavant, N. Gauthier, L. Abed, K.G. Soni, G. Yang, G.A. Mitchell, Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis, *Hepatology* 54 (2011) 122–132.
- [10] B.N. Reid, G.P. Ables, O.A. Otlivanchik, G. Schoiswohl, R. Zechner, W.S. Blaner, I.J. Goldberg, R.F. Schwabe, S.C. Chua Jr., L.S. Huang, Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis, *J. Biol. Chem.* 283 (2008) 13087–13099.
- [11] G. Haemmerle, A. Lass, R. Zimmermann, G. Gorkiewicz, C. Meyer, J. Rozman, G. Heldmaier, R. Maier, C. Theussl, S. Eder, D. Kratky, E.F. Wagner, M. Klingenspor, G. Hoefler, R. Zechner, Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase, *Science* 312 (2006) 734–737.
- [12] R. Lehner, D.E. Vance, Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol, *Biochem. J.* 343 (Pt 1) (1999) 1–10.
- [13] D. Gilham, S. Ho, M. Rasouli, P. Martres, D.E. Vance, R. Lehner, Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion, *FASEB J.* 17 (2003) 1685–1687.
- [14] D. Gilham, M. Alam, W. Gao, D.E. Vance, R. Lehner, Triacylglycerol hydrolase is localized to the endoplasmic reticulum by an unusual retrieval sequence where it participates in VLDL assembly without utilizing VLDL lipids as substrates, *Mol. Biol. Cell* 16 (2005) 984–996.
- [15] E. Wei, M. Alam, F. Sun, L.B. Agellon, D.E. Vance, R. Lehner, Apolipoprotein B and triacylglycerol secretion in human triacylglycerol hydrolase transgenic mice, *J. Lipid Res.* 48 (2007) 2597–2606.
- [16] E. Wei, Y. Ben Ali, J. Lyon, H. Wang, R. Nelson, V.W. Dolinsky, J.R. Dyck, G. Mitchell, G.S. Korbutt, R. Lehner, Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure, *Cell Metab.* 11 (2010) 183–193.
- [17] S. Qiu, N. Bergeron, L. Kotite, R.M. Krauss, A. Bensadoun, R.J. Havel, Metabolism of lipoproteins containing apolipoprotein B in hepatic lipase-deficient mice, *J. Lipid Res.* 39 (1998) 1661–1668.
- [18] G.E. Homanics, H.V. de Silva, J. Osada, S.H. Zhang, H. Wong, J. Borensztajn, N. Maeda, Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene, *J. Biol. Chem.* 270 (1995) 2974–2980.
- [19] J. Fan, J. Wang, A. Bensadoun, S.J. Lauer, Q. Dang, R.W. Mahley, J.M. Taylor, Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 8724–8728.
- [20] H.L. Dichek, W. Brecht, J. Fan, Z.S. Ji, S.P. McCormick, H. Akeefe, L. Conzo, D.A. Sanan, K.H. Weisgraber, S.G. Young, J.M. Taylor, R.W. Mahley, Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake, *J. Biol. Chem.* 273 (1998) 1896–1903.
- [21] G. Lambert, M.J. Amar, P. Martin, J. Fruchart-Najib, B. Foger, R.D. Shamburek, H.B. Brewer Jr., S. Santamarina-Fojo, Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo, *J. Lipid Res.* 41 (2000) 667–672.
- [22] G. Lambert, M.B. Chase, K. Dugi, A. Bensadoun, H.B. Brewer Jr., S. Santamarina-Fojo, Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1, *J. Lipid Res.* 40 (1999) 1294–1303.
- [23] F. Rinninger, W.A. Mann, T. Kaiser, S. Ahle, N. Meyer, H. Greten, Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters by human Hep 3B hepatoma cells in culture, *Atherosclerosis* 141 (1998) 273–285.
- [24] M. Brundt, J. Heeren, H. Greten, F. Rinninger, Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI, *J. Lipid Res.* 44 (2003) 1020–1032.
- [25] A.J. Verhoeven, B.P. Neve, H. Jansen, Secretion and apparent activation of human hepatic lipase requires proper oligosaccharide processing in the endoplasmic reticulum, *Biochem. J.* 337 (Pt 1) (1999) 133–140.
- [26] F. Sultan, D. Lagrange, H. Jansen, S. Griglio, Inhibition of hepatic lipase activity impairs chylomicron remnant-removal in rats, *Biochim. Biophys. Acta* 1042 (1990) 150–152.
- [27] S. Shafi, S.E. Brady, A. Bensadoun, R.J. Havel, Role of hepatic lipase in the uptake and processing of chylomicron remnants in rat liver, *J. Lipid Res.* 35 (1994) 709–720.
- [28] H. Jansen, A.J. Verhoeven, E.J. Sijbrands, Hepatic lipase: a pro- or anti-atherogenic protein? *J. Lipid Res.* 43 (2002) 1352–1362.
- [29] F. Kuipers, M.C. Jong, Y. Lin, M. Eck, R. Havinga, V. Bloks, H.J. Verkade, M.H. Hofker, H. Moshage, T.J. Berkel, R.J. Vonk, L.M. Havekes, Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes, *J. Clin. Invest.* 100 (1997) 2915–2922.
- [30] A.R. Mensenkamp, M.J. Van Luyn, R. Havinga, B. Teusink, I.J. Waterman, C.J. Mann, B.M. Elzinga, H.J. Verkade, V.A. Zammit, L.M. Havekes, C.C. Shoulders, F. Kuipers, The transport of triglycerides through the secretory pathway of hepatocytes is impaired in apolipoprotein E deficient mice, *J. Hepatol.* 40 (2004) 599–606.
- [31] A.R. Mensenkamp, M.C. Jong, H. van Goor, M.J. van Luyn, V. Bloks, R. Havinga, P.J. Voshol, M.H. Hofker, K.W. van Dijk, L.M. Havekes, F. Kuipers, Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver, *J. Biol. Chem.* 274 (1999) 35711–35718.
- [32] X.C. Jiang, Z. Li, R. Liu, X.P. Yang, M. Pan, L. Lagrost, E.A. Fisher, K.J. Williams, Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants, *J. Biol. Chem.* 280 (2005) 18336–18340.
- [33] X.C. Jiang, S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao, A.R. Tall, Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency, *Nat. Med.* 7 (2001) 847–852.
- [34] J. Twiss, D.L. Gillian-Daniel, A. Tebon, L. Wang, P.H. Barrett, A.D. Attie, The role of the LDL receptor in apolipoprotein B secretion, *J. Clin. Invest.* 105 (2000) 521–532.
- [35] A.J. Verhoeven, B.P. Neve, H. Jansen, Intracellular activation of rat hepatic lipase requires transport to the Golgi compartment and is associated with a decrease in sedimentation velocity, *J. Biol. Chem.* 275 (2000) 9332–9339.
- [36] M. Bamji-Mirza, M. Sundaram, S. Zhong, E.F. Yao, R.J. Parks, Z. Yao, Secretion of triacylglycerol-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase, *J. Lipid Res.* 52 (2011) 540–548.
- [37] V.W. Dolinsky, S. Sipione, R. Lehner, D.E. Vance, The cloning and expression of a murine triacylglycerol hydrolase cDNA and the structure of its corresponding gene, *Biochim. Biophys. Acta* 1532 (2001) 162–172.
- [38] M. Robbi, H. Beaufay, Immunological characterization and biosynthesis of pI-6.4 esterase, a carboxylesterase of rat liver microsomal extracts, *Biochem. J.* 254 (1988) 51–57.

- 640 [39] K.W. Ko, B. Erickson, R. Lehner, Es-x/Ces1 prevents triacylglycerol accumulation in
641 McArdle-RH7777 hepatocytes, *Biochim. Biophys. Acta* 1791 (2009) 1133–1143.
- 642 [40] V. Lo, B. Erickson, M. Thomason-Hughes, K.W. Ko, V.W. Dolinsky, R. Nelson, R.
643 Lehner, Arylacetylase deacetylase attenuates fatty-acid-induced triacylglycerol
644 accumulation in rat hepatoma cells, *J. Lipid Res.* 51 (2010) 368–377.
- 645 [41] H. Wang, E. Wei, A.D. Quiroga, X. Sun, N. Touret, R. Lehner, Altered lipid droplet
646 dynamics in hepatocytes lacking triacylglycerol hydrolase expression, *Mol. Biol.*
647 *Cell* 21 (2010) 1991–2000.
- 648 [42] D. Gilham, R. Lehner, Techniques to measure lipase and esterase activity in vitro,
649 *Methods* 36 (2005) 139–147.
- 650 [43] D. Sahoo, T.C. Trischuk, T. Chan, V.A. Drover, S. Ho, G. Chimini, L.B. Agellon, R.
651 Agnihotri, G.A. Francis, R. Lehner, ABCA1-dependent lipid efflux to apolipoprotein
652 A-I mediates HDL particle formation and decreases VLDL secretion from murine
653 hepatocytes, *J. Lipid Res.* 45 (2004) 1122–1131.
- 654 [44] V.W. Dolinsky, D. Gilham, M. Alam, D.E. Vance, R. Lehner, Triacylglycerol hydrolase:
655 role in intracellular lipid metabolism, *Cell. Mol. Life Sci.* 61 (2004) 1633–1651.
- 656 [45] A.L. White, D.L. Graham, J. LeGros, R.J. Pease, J. Scott, Oleate-mediated stimulation
657 of apolipoprotein B secretion from rat hepatoma cells. A function of the ability of
658 apolipoprotein B to direct lipoprotein assembly and escape presecretory degrada-
659 tion, *J. Biol. Chem.* 267 (1992) 15657–15664.
- 660 [46] P. Stillemark, J. Boren, M. Andersson, T. Larsson, S. Rustaeus, K.A. Karlsson, S.O.
661 Olofsson, The assembly and secretion of apolipoprotein B-48-containing very low
662 density lipoproteins in McA-RH7777 cells, *J. Biol. Chem.* 275 (2000) 10506–10513.
- 663 [47] Y. Wang, K. Tran, Z. Yao, The activity of microsomal triglyceride transfer protein is
664 essential for accumulation of triglyceride within microsomes in McA-RH7777
665 cells. A unified model for the assembly of very low density lipoproteins, *J. Biol.*
666 *Chem.* 274 (1999) 27793–27800.
- 667 [48] M.M. Hussain, J. Shi, P. Dreizen, Microsomal triglyceride transfer protein and its
668 role in apoB-lipoprotein assembly, *J. Lipid Res.* 44 (2003) 22–32.
- 669 [49] C.A. Alexander, R.L. Hamilton, R.J. Havel, Subcellular localization of B apoprotein
670 of plasma lipoproteins in rat liver, *J. Cell Biol.* 69 (1976) 241–263.
- 671 [50] M. Raabe, M.M. Veniant, M.A. Sullivan, C.H. Zlot, J. Bjorkegren, L.B. Nielsen, J.S.
672 Wong, R.L. Hamilton, S.G. Young, Analysis of the role of microsomal triglyceride
transfer protein in the liver of tissue-specific knockout mice, *J. Clin. Invest.* 103
(1999) 1287–1298.
- [51] A. Kulinski, S. Rustaeus, J.E. Vance, Microsomal triacylglycerol transfer protein is
required for luminal accretion of triacylglycerol not associated with ApoB, as
well as for ApoB lipidation, *J. Biol. Chem.* 277 (2002) 31516–31525.
- [52] V. Lo, B. Erickson, M. Thomason-Hughes, K.W. Ko, V.W. Dolinsky, R. Nelson, R.
Lehner, Arylacetylase deacetylase attenuates fatty-acid-induced triacylglycerol
accumulation in rat hepatoma cells, *J. Lipid Res.* 51 368–377.
- [53] K.T. Ong, M.T. Mashek, S.Y. Bu, A.S. Greenberg, D.G. Mashek, Adipose triglyceride
lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty
acid signaling and partitioning, *Hepatology* 53 (2011) 116–126.
- [54] A. Zambon, S.S. Deeb, J.E. Hokanson, B.G. Brown, J.D. Brunzell, Common variants in
the promoter of the hepatic lipase gene are associated with lower levels of hepatic
lipase activity, buoyant LDL, and higher HDL2 cholesterol, *Arterioscler. Thromb.*
Vasc. Biol. 18 (1998) 1723–1729.
- [55] A. Isaacs, F.A. Sayed-Tabatabaei, O.T. Njajou, J.C. Witteman, C.M. van Duijn, The
–514 C→T hepatic lipase promoter region polymorphism and plasma lipids: a
meta-analysis, *J. Clin. Endocrinol. Metab.* 89 (2004) 3858–3863.
- [56] S. Santamarina-Fojo, H. Gonzalez-Navarro, L. Freeman, E. Wagner, Z. Nong, Hepatic
lipase, lipoprotein metabolism, and atherogenesis, *Arterioscler. Thromb. Vasc.*
Biol. 24 (2004) 1750–1754.
- [57] R.A. Hegele, J.A. Little, C. Vezina, G.F. Maguire, L. Tu, T.S. Wolever, D.J. Jenkins, P.W.
Connelly, Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic
characteristics, *Arterioscler. Thromb.* 13 (1993) 720–728.
- [58] M. Tilly-Kiesi, E.J. Schaefer, P. Knudsen, F.K. Welty, G.G. Dolnikowski, M.R.
Taskinen, A.H. Lichtenstein, Lipoprotein metabolism in subjects with hepatic
lipase deficiency, *Metabolism* 53 (2004) 520–525.
- [59] I.L. Ruel, P. Couture, J.S. Cohn, B. Lamarche, Plasma metabolism of apoB-
containing lipoproteins in patients with hepatic lipase deficiency, *Atherosclerosis*
180 (2005) 355–366.
- [60] S.S. Deeb, A. Zambon, M.C. Carr, A.F. Ayyobi, J.D. Brunzell, Hepatic lipase and
dyslipidemia: interactions among genetic variants, obesity, gender, and diet, *J.*
Lipid Res. 44 (2003) 1279–1286.

707

UNCORRECTED